General Information
Mouse: (CB57BL/6J X CBA/ca) X Syn-/-CB57BL/6JOla
Expression of human C-terminal-truncated (1-120) wild type alpha-synuclein under the control of the rat tyrosine hydroxylase (TH) promoter.
Endogenous rat alpha synuclein: No (backcrossed to CB57BL/6JOla lacking alpha-synuclein)
Corresponding human genotype: Not reported but truncated alpha-synuclein is enriched in human Lewy body extracts
Transgene insertion: not specified
References: Tofaris 2006; Michell 2007
Transgene expression
- 6 weeks – 14 months: High transgene expression is observed in SN and olfactory bulb. Protein expression is observed in the somatodendritic compartment of TH-positive neurons (SN) and in terminals (striatum). Truncated alpha-synuclein expression is also observed in the locus ceruleus.
Neurodegeneration
- Up to 14 months: No loss of TH-positive neurons is detected.
Dopamine Homeostasis
- 1 months: No changes in striatal dopamine levels
- 2-12 months: 30% reduction of dopamine and homovanillic acid levels are observed in the striatum
Inclusions
- Up to 12 months: Inclusions positive for the truncated alpha-synuclein are observed in the olfactory bulb at all ages.
- 12-14 months: perinuclear inclusion of truncated alpha-synuclein is observed in the SN.
Motor Behaviours
- 6 months: No significant changes in total spontaneous activity are detected
- 18 months: Reduced spontaneous activity is observed.
Response to L-DOPA treatment
- Not reported
Non motor Behaviours
- Not reported
Electrophysiology
- Not reported
Neuroinflammation
- Up to 14 months: Progressive increase of inflammatory response is observed